TOP TIERMARKET NEWSWIRE

News & sentiment

PYXIS ONCOLOGY INC (PYXS) — News & AI sentiment

PYXIS ONCOLOGY INC (PYXS) news roundup. 23 stories in the past week, 27 over 30 days. Average 30-day sentiment is 54.2/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

23

avg sentiment 55.3/100

30d stories

27

avg sentiment 54.2/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

PYXS news in the last 24 hours, 7 days, 30 days and 90 days

How much PYXS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	PYXS stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	23	55.3/100	PYXS headlines →
Last 30 days	27	54.2/100	PYXS headlines →
Last 90 days	38	51.6/100	PYXS headlines →

Latest stories on PYXS

Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery

Seeking Alpha34 · bearishanalyst

2d ago

Pyxis Oncology stock price target raised to $8 by H.C. Wainwright

Investing.com Analyst Ratings61 · neutralanalyst

3d ago

Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright

The Fly63 · neutralanalyst

3d ago

Wells Fargo raises Pyxis Oncology stock price target on MICVO data

Investing.com Analyst Ratings61 · neutralanalyst

3d ago

Wedbush raises Pyxis Oncology stock price target on trial data

Investing.com Analyst Ratings61 · neutralanalyst

3d ago

Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript

Seeking Alpha55 · neutralproduct/pr

3d ago

Pyxis Oncology price target raised to $19 from $12 at Wells Fargo

The Fly61 · neutralanalyst

4d ago

Pyxis Oncology shares fall 7% despite updated MICVO trial results

InvestorsHub42 · neutralearnings

4d ago

Pyxis Oncology stock falls 7% despite positive trial data

Investing.com Markets47 · neutralgeneral

4d ago

Pyxis slides after new early-stage trial data for lead asset in head and neck cancer

Seeking Alpha34 · bearishproduct/pr

4d ago

Pyxis Oncology Reports Promising MICVO Phase 1 Results

TipRanks67 · bullishproduct/pr

4d ago

Pyxis Oncology announces updated results from micvotabart pelidotin study

The Fly63 · neutralproduct/pr

4d ago

Pyxis Oncology, Inc. (PYXS) files 8-K

SEC 8-K50 · neutralgeneral

4d ago

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

StockTitan67 · bullishproduct/pr

4d ago

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

GlobeNewswire71 · bullishproduct/pr

4d ago

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

StockTitan56 · neutralproduct/pr

5d ago

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

GlobeNewswire63 · neutralproduct/pr

5d ago

Pyxis Oncology Elevates Thomas Civik to Permanent CEO

TipRanks55 · neutralgeneral

5d ago

Pyxis Oncology appoints Thomas Civik as CEO, chairman

The Fly50 · neutralgeneral

5d ago

Pyxis Oncology appoints Thomas Civik as CEO and Chairman

Seeking Alpha55 · neutralgeneral

5d ago

Pyxis Oncology, Inc. (PYXS) files 8-K

SEC 8-K50 · neutralgeneral

5d ago

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

Business Insider50 · neutralgeneral

5d ago

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

GlobeNewswire55 · neutralgeneral

5d ago

Pyxis Oncology to Participate in Upcoming Investor Conferences

StockTitan56 · neutralgeneral

Sep 1

Pyxis Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire56 · neutralgeneral

Sep 1

Open PYXS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →